Naofumi Kameyama

Naofumi Kameyama

Auto-generated profile, based on publicly available information

Naofumi Kameyama

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
KMKatsunori Masaki
Katsunori Masaki
HTHiroki Tateno
Hiroki Tateno
NKNaofumi Kameyama
Naofumi Kameyama
EMEriko Morino
Eriko Morino
RWRiri Watanabe
Riri Watanabe
KFKoichi Fukunaga
Koichi Fukunaga
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mobile applications have been considered to provide active and continuous support for smoking cessation. However, it is yet to be known whether a smoking cessation smartphone application improves long-term abstinence rates in nicotine-dependent patients. Objective: We aim to evaluate the long-term abstinence effect of a novel smartphone application, CureApp Smoking Cessation (CASC), in patients with nicotine dependence. Methods: This study was a prospective, interventional, multicenter, single-arm study. We provided the CASC application to all the participants, who used it daily for 24 weeks. The CASC application includes features to maximize the therapeutic effect of pharmacological therapies and counseling at outpatient clinics for smoking cessation. The primary endpoint was a continuous abstinence rate (CAR) from weeks 9 to 24, while secondary endpoints were CARs from weeks 9 to 12 and 9 to 52. Results: Of the 56 adult smokers recruited, one did not download the application; therefore, 55 participants constituted the full analysis sample. The CAR from weeks 9 to 24 was 63.6% (35/55; 95% confidence interval [CI]: 51.3% – 76.0%), while the CARs from weeks 9 to 12 and 9 to 52 were 76.4% (42/55; 95% CI: 65.2% – 87.5%) and 58.2% (32/55; 95% CI: 45.6% – 70.8%), respectively. These CARs were better than the results of the national survey on outpatient clinics with regard to smoking cessation under the National Health Insurance Program and that of the varenicline phase Ⅲ trial in Japan and the United States. There was only one participant who dropped out during the 12 weeks of the treatment period. This treatment decreased the scores related to withdrawal and craving symptoms. Conclusions: The addition of CASC to usual smoking cessation therapies resulted in high CARs, high patient retention rates, and improvement of cessation-related symptoms. The smartphone application CASC is a feasible and useful tool to help long-term continuous abstinence that can be combined with a standard smoking cessation treatment program. Clinical Trial: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN ID: UMIN000020123).

1 December 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
NKNaofumi Kameyama
Naofumi Kameyama
TSTakashi Sato
Takashi Sato
DADaisuke Arai
Daisuke Arai
DFDaisuke Fujisawa
Daisuke Fujisawa
MTMari Takeuchi
Mari Takeuchi
KSKenzo Soejima
Kenzo Soejima
PURPOSE: Patients' values and priorities in their lives should be appreciated from an early phase of incurable diseases such as advanced cancer. However, studies examining these characteristics have been lacking. This study attempted to determine what patients with advanced lung cancer valued most, once they had been diagnosed, and any associated factors. METHODS: Patients with newly diagnosed advanced lung cancer (N = 248) were enrolled in a questionnaire survey conducted at 16 hospitals in Japan. Their priorities were assessed using a free-text response to the question what is the most important thing to you now? at the time of diagnosis and 3 months after diagnosis. The free-text responses were classified into 10 categories for quantification. The clinical characteristics associated with the category describing daily life were further examined. RESULTS: Free-text comments were obtained from 103 (44.0%) and 66 (42.6%) patients at the time of diagnosis and at 3 months, respectively. The most frequent categories were family (at diagnosis: 50.5%; at 3 months: 50.0%) and daily life (at diagnosis: 33.0%; at 3 months: 36.4%), followed by health (at diagnosis: 32.0%; at 3 months: 27.3%) at both time points. The patients mentioning daily life, the issues related to how to spend daily life, showed significantly higher total scores and functional well-being subscale scores on the Functional Assessment of Cancer Therapy-Lung scale at both time points and lower depression scores at diagnosis and lower anxiety scores at 3 months on the Hospital Anxiety and Depression Scale. CONCLUSION: Family and daily life were highly valued by patients with advanced lung cancer at diagnosis. A better quality of life and better mood were associated with mentioning daily life, which should be taken into account in care planning to maintain patients' involvement in daily life even with incurable diseases.

5 November 2018 in JMIR Preprints
Verified
Preprint
Open access
KMKatsunori Masaki
Katsunori Masaki
HTHiroki Tateno
Hiroki Tateno
NKNaofumi Kameyama
Naofumi Kameyama
EMEriko Morino
Eriko Morino
RWRiri Watanabe
Riri Watanabe
KFKoichi Fukunaga
Koichi Fukunaga
BACKGROUND Mobile apps have been considered to provide active and continuous support for smoking cessation. However, it is yet to be known whether a smoking cessation smartphone app improves long-term abstinence rates in nicotine-dependent patients. OBJECTIVE This study aimed to evaluate the long-term abstinence effect of a novel smartphone app, CureApp Smoking Cessation (CASC), in patients with nicotine dependence. METHODS In this prospective, interventional, multicenter, single-arm study, we provided the CASC app to all the participants, who used it daily for 24 weeks. The CASC app includes features to maximize the therapeutic effect of pharmacological therapies and counseling at outpatient clinics for smoking cessation. The primary endpoint was a continuous abstinence rate (CAR) from weeks 9 to 24, whereas secondary endpoints were CARs from weeks 9 to 12 and 9 to 52. RESULTS Of the 56 adult smokers recruited, 1 did not download the app; therefore, 55 participants constituted the full analysis sample. The CAR from weeks 9 to 24 was 64% (35/55, 95% CI 51%-76%), whereas the CARs from weeks 9 to 12 and 9 to 52 were 76% (42/55, 95% CI 65%-88%) and 58% (32/55, 95% CI 46%-71%), respectively. These CARs were better than the results of the national survey on outpatient clinics with regard to smoking cessation under the National Health Insurance Program and that of the varenicline phase 3 trial in Japan and the United States. There was only 1 participant who dropped out during the 12 weeks of the treatment period. This treatment decreased the scores related to withdrawal and craving symptoms. CONCLUSIONS The addition of CASC to usual smoking cessation therapies resulted in high CARs, high patient retention rates, and improvement of cessation-related symptoms. The smartphone app CASC is a feasible and useful tool to help long-term continuous abstinence that can be combined with a standard smoking cessation treatment program.